Antibacterial antibodies gain traction - PubMed (original) (raw)

• PMID: 26514853
• DOI: 10.1038/nrd4770

Antibacterial antibodies gain traction

Chris Morrison. Nat Rev Drug Discov. 2015 Nov.

No abstract available

PubMed Disclaimer

Similar articles

• A guiding hand for antibiotics.
  Jones D. Jones D. Nat Rev Drug Discov. 2011 Mar;10(3):161-2. doi: 10.1038/nrd3400. Nat Rev Drug Discov. 2011. PMID: 21358722 No abstract available.
• The antibacterial drugs market.
  Kresse H, Belsey MJ, Rovini H. Kresse H, et al. Nat Rev Drug Discov. 2007 Jan;6(1):19-20. doi: 10.1038/nrd2226. Nat Rev Drug Discov. 2007. PMID: 17269159 No abstract available.
• Immunoglobulins in antibacterial defense.
  Nydegger UE. Nydegger UE. Curr Stud Hematol Blood Transfus. 1992;(59):146-62. doi: 10.1159/000429611. Curr Stud Hematol Blood Transfus. 1992. PMID: 1572212 Review. No abstract available.
• Emerging drugs for bacterial urinary tract infections.
  Wagenlehner FM, Weidner W, Naber KG. Wagenlehner FM, et al. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. doi: 10.1517/14728214.10.2.275. Expert Opin Emerg Drugs. 2005. PMID: 15934867 Review.
• The urgent need for new antibacterial agents.
  Wise R; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Wise R, et al. J Antimicrob Chemother. 2011 Sep;66(9):1939-40. doi: 10.1093/jac/dkr261. Epub 2011 Jun 23. J Antimicrob Chemother. 2011. PMID: 21700627 No abstract available.

Cited by

• Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244.
  Horspool AM, Sen-Kilic E, Malkowski AC, Breslow SL, Mateu-Borras M, Hudson MS, Nunley MA, Elliott S, Ray K, Snyder GA, Miller SJ, Kang J, Blackwood CB, Weaver KL, Witt WT, Huckaby AB, Pyles GM, Clark T, Al Qatarneh S, Lewis GK, Damron FH, Barbier M. Horspool AM, et al. Front Cell Infect Microbiol. 2023 Apr 14;13:1117844. doi: 10.3389/fcimb.2023.1117844. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37124031 Free PMC article.
• Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms.
  Ahmed S, Ahmed MZ, Rafique S, Almasoudi SE, Shah M, Jalil NAC, Ojha SC. Ahmed S, et al. Biomed Res Int. 2023 Jan 23;2023:5250040. doi: 10.1155/2023/5250040. eCollection 2023. Biomed Res Int. 2023. PMID: 36726844 Free PMC article. Review.
• Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.
  Ren E, Liu C, Lv P, Wang J, Liu G. Ren E, et al. Adv Sci (Weinh). 2021 Nov;8(21):e2100460. doi: 10.1002/advs.202100460. Epub 2021 Sep 8. Adv Sci (Weinh). 2021. PMID: 34494387 Free PMC article.
• Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics.
  Sintchenko V, Timms V, Sim E, Rockett R, Bachmann N, O'Sullivan M, Marais B. Sintchenko V, et al. Front Med (Lausanne). 2021 Apr 13;8:641260. doi: 10.3389/fmed.2021.641260. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33928102 Free PMC article.
• Recent advances in the treatment of C. difficile using biotherapeutic agents.
  Giau VV, Lee H, An SSA, Hulme J. Giau VV, et al. Infect Drug Resist. 2019 Jun 10;12:1597-1615. doi: 10.2147/IDR.S207572. eCollection 2019. Infect Drug Resist. 2019. PMID: 31354309 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information